Loading
HKSEConsumer DefensivePackaged Foods
Latest quote
HK$2.38
−HK$0.05 · -2.06%
Besunyen Holdings Company Limited, established in Beijing, China, in 2000, functions as a subsidiary of Foreshore Holding Group Limited. The company's core operations encompass the research, development, production, and distribution of therapeutic tea products and pharmaceutical goods throughout the People's Republic of China. Its product range includes a variety of therapeutic teas, prominently featuring the Besunyen brand, alongside specific offerings such as herbal tea, Besunyen Detox, and Besunyen slimming tea. Furthermore, functional teas, such as Besunyen Fit Tea, are also part of its portfolio. Within its pharmaceutical segment, Besunyen markets LARLLY Orlistat for weight loss and manufactures and sells over-the-counter (OTC) medications, including the Besunyen Orlistat weight-loss capsule. Its products reach consumers via an extensive distribution network that includes OTC pharmacies, retail locations in shopping centers and supermarkets, a network of distributors and sub-distributors, and various online e-commerce channels.
Latest quote
HK$2.38
−HK$0.05 · -2.06%
Besunyen Holdings Company Limited, established in Beijing, China, in 2000, functions as a subsidiary of Foreshore Holding Group Limited. The company's core operations encompass the research, development, production, and distribution of therapeutic tea products and pharmaceutical goods throughout the People's Republic of China. Its product range includes a variety of therapeutic teas, prominently featuring the Besunyen brand, alongside specific offerings such as herbal tea, Besunyen Detox, and Besunyen slimming tea. Furthermore, functional teas, such as Besunyen Fit Tea, are also part of its portfolio. Within its pharmaceutical segment, Besunyen markets LARLLY Orlistat for weight loss and manufactures and sells over-the-counter (OTC) medications, including the Besunyen Orlistat weight-loss capsule. Its products reach consumers via an extensive distribution network that includes OTC pharmacies, retail locations in shopping centers and supermarkets, a network of distributors and sub-distributors, and various online e-commerce channels.
Day range
Current HK$2.38
52-week range
Current HK$2.38
Historical prices · Market data may be delayed.
Besunyen Holdings Company Limited, established in Beijing, China, in 2000, functions as a subsidiary of Foreshore Holding Group Limited. The company's core operations encompass the research, development, production, and distribution of therapeutic tea products and pharmaceutical goods throughout the People's Republic of China. Its product range includes a variety of therapeutic teas, prominently featuring the Besunyen brand, alongside specific offerings such as herbal tea, Besunyen Detox, and Besunyen slimming tea. Furthermore, functional teas, such as Besunyen Fit Tea, are also part of its portfolio. Within its pharmaceutical segment, Besunyen markets LARLLY Orlistat for weight loss and manufactures and sells over-the-counter (OTC) medications, including the Besunyen Orlistat weight-loss capsule. Its products reach consumers via an extensive distribution network that includes OTC pharmacies, retail locations in shopping centers and supermarkets, a network of distributors and sub-distributors, and various online e-commerce channels.
Day range
Current HK$2.38
52-week range
Current HK$2.38
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 494.32M CNY | 484.3M CNY | 542.88M CNY | 801.34M CNY | 1.1B CNY |
| Cost of goods sold | 147.74M CNY | 158.46M CNY | 196.66M CNY | 308.75M CNY | 402.6M CNY |
| Gross profit | 346.58M CNY | 325.84M CNY | 346.22M CNY | 492.59M CNY | 698.55M CNY |
| Research and development | 9.5M CNY | 29.36M CNY | 34.92M CNY | 33.87M CNY | 93.1M CNY |
| Selling, general, and administrative | 278.4M CNY | 247.64M CNY | 470.73M CNY | 489.39M CNY | 695.88M CNY |
| Operating expenses | 319.09M CNY | 304.29M CNY | 496.51M CNY | 523.97M CNY | 786.65M CNY |
| Interest income | 364.32K CNY | 7.82M CNY | 5.83M CNY | 1.82M CNY | 11.2M CNY |
| Interest expense | 360.42K CNY | 228K CNY | 2M CNY | 7.65M CNY | 5.42M CNY |
| Depreciation and amortization | 14.8M CNY | 13.29M CNY | 15.73M CNY | 18.28M CNY | 55.54M CNY |
| Operating income | 27.5M CNY | 21.55M CNY | −150.29M CNY | −31.38M CNY | −88.1M CNY |
| Net income | 20.44M CNY | 14.8M CNY | −299.24M CNY | −99.09M CNY | −145.71M CNY |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.